Cardiometabolic associations of SGLT-2 inhibitors on epicardial adiposity and left ventricular function in type 2 diabetes mellitus with coronary artery disease: insights from Malaysian EpiCAD study
SGLT-2 inhibitor diabetes drugs reduce harmful belly fat around the heart and improve heart function in Asian patients with coronary disease.
In 302 Malaysian T2DM patients with coronary artery disease, SGLT-2 inhibitors over 6 months produced marked reductions in epicardial adipose tissue (-1.5mm vs +0.6mm, p<0.001) and significant improvements in LV ejection fraction and mass compared to controls. This study provides Asian population-specific evidence for SGLT-2i cardioprotective effects beyond glycemic control, with distinct cardiometabolic adiposity traits.
What the study was
- Study design
- Prospective observational cohort, paired pre/post 6-month analysis
- Population
- Malaysian patients with T2DM and CAD; n=302 completers (151 per group)
- Sample size
- 302
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Sci Rep
Why it surfaced
Prospective cohort demonstrating SGLT-2i reduces epicardial fat and improves LV remodeling in Asian T2DM+CAD patients — an underrepresented population in prior SGLT-2i trials. EAT reduction independent of glycemic changes suggests direct cardiac mechanism.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.